Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03037385 |
|
Recruitment Status :
Completed
First Posted : January 31, 2017
Last Update Posted : April 11, 2024
|
Sponsor:
Hoffmann-La Roche
Information provided by (Responsible Party):
Hoffmann-La Roche
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| RET-altered Non Small Cell Lung Cancer Medullary Thyroid Cancer RET-altered Papillary Thyroid Cancer RET-altered Colon Cancer RET-altered Solid Tumors Lung Neoplasm Carcinoma, Non-Small-Cell Lung Thyroid Diseases Thyroid Neoplasm Thyroid Cancer, Papillary Carcinoma, Neuroendocrine Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Disease Carcinoma, Bronchogenic Bronchial Neoplasms Endocrine System Diseases Endocrine Gland Neoplasm Head and Neck Neoplasms Adenocarcinoma, Papillary Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Colonic Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasm Digestive System Disease Gastrointestinal Disease Colonic Diseases Intestinal Disease | Drug: pralsetinib (BLU-667) | Phase 1 Phase 2 |
Expanded Access : An investigational treatment associated with this study has been approved for sale to the public. More info ...
The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll participants with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, or the participants must be intolerant to or the Investigator has determined that treatment with standard therapy is not appropriate, or there must be no accepted standard therapy for their disease.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 589 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Phase 1 (Complete):
Phase 2 (400mg QD):
|
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors |
| Actual Study Start Date : | March 17, 2017 |
| Actual Primary Completion Date : | March 21, 2024 |
| Actual Study Completion Date : | March 21, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Lung cancer
Drug Information
available for:
Pralsetinib
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1 Dose Escalation
Multiple doses of pralsetinib (BLU-667) for oral administration.
|
Drug: pralsetinib (BLU-667)
pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
Other Name: BLU-667 |
|
Experimental: Phase 2 Dose Expansion
Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
|
Drug: pralsetinib (BLU-667)
pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
Other Name: BLU-667 |
Primary Outcome Measures :
- (Phase 1) Determination of Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib [ Time Frame: Cycle 1 (28 days) of treatment for MTD and at the end of every cycle (28 days) for RP2D for approximately 12 months or earlier if participant terminates from the study ]
- (Phase 1) Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Every cycle (28 days) for approximately 12 months or earlier if participant terminates from the study, and 30 days after the last dose ]
- (Phase 2) Overall Response Rate (ORR) [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle ]As assessed by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or Response Assessment in Neuro-Oncology (RANO), as appropriate per tumor type
- (Phase 2) Number of Participants with AEs and SAEs [ Time Frame: Every cycle (28 days) for approximately 24 months or earlier if participant terminates from the study, and 30 days after the last dose ]
Secondary Outcome Measures :
- (Phase 1) ORR [ Time Frame: Approximately every 8 weeks during treatment, 14 days after the last dose, and every 3 months after the last dose (Up to 12 months) in participants without progressive disease ]As assessed by RECIST v1.1 or RANO, as appropriate per tumor type
- (Phase 1) RET Gene Status and Correlation Between RET Gene Status and ORR, CBR, DOR, DCR, PFS and Other Antineoplastic Measures [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 12 months) ]Clinical Benefit Rate (CBR), Duration of Response (DOR), Disease Control Rate (DCR), Progression Free Survival (PFS)
- (Phase 2) CBR [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle ]
- (Phase 2) DOR [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle ]
- (Phase 2) DCR [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle ]
- (Phase 2) PFS [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 84 months) ]
- (Phase 2) Overall Survival (OS) [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 84 months) ]
- (Phase 2) RET Gene Status and Correlation Between RET Gene Status and ORR, CBR, DOR, DCR and Other Antineoplastic Measures [ Time Frame: On Day 1 of Cycle 1 (each cycle is of 28 days), 2 and 3 and every other cycle thereafter up to Cycle 13 ]RET gene status (i.e. gene fusion partner or primary mutation and, for MTC, whether hereditary or sporadic)
- (Phases 1 and 2) Pharmacokinetic Parameters Including Maximum Plasma Drug Concentration (Cmax) [ Time Frame: Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4 ]
- (Phases 1 and 2) Pharmacokinetic Parameters Including Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC0-24) [ Time Frame: Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4 ]
- (Phases 1 and 2) Pharmacokinetic Parameters Including Terminal Elimination Half-life (t1/2) [ Time Frame: Approximately every 2 weeks in Cycle 1 and monthly through Cycle 4 ]
- (Phase 2) Electrocardiogram (ECG) Assessment Using QT Analysis [ Time Frame: Effects of BLU-667 on ECG parameters on Cycle 1 Day 1 and Cycle 1 Day 15 ]Will be measured from lead II and will be corrected for heart rate (QTc)n using Fridericia's correction factors
- (Phases 1 and 2) Pharmacodynamic Parameters Including Changes in Blood Calcitonin [ Time Frame: Approximately every 2 weeks in Cycle 1 and monthly through Cycle 3 and every other month through Cycle 13 ]MTC participants only
- (Phases 1 and 2) Pharmacodynamic Parameters Including Tumor Marker, Carcinoembryonic Antigen (CEA) [ Time Frame: Approximately every 2 weeks in Cycle 1 and monthly through Cycle 3 and every other month through Cycle 13 ]MTC participants only
- (Phase 2) Assess Intracranial Response Rate and Time to Intracranial Progression in Participants With NSCLC [ Time Frame: Approximately every 8 weeks or 16 weeks based on the treatment cycle ]Target by RECIST v1.1 or RANO
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
-
Diagnosis during dose escalation (Phase 1) - Pathologically documented, definitively diagnosed non-resectable advanced solid tumor.
- All participants treated at doses > 120 mg per day must have MTC, or a RET-altered solid tumor per local assessment of tumor tissue and/or blood.
-
Diagnosis during dose expansion (Phase 2) - All participants (with the exception of participants with MTC enrolled in Groups 3, 4, and 9) must have an oncogenic RET-rearrangement/fusion or mutation (excluding synonymous, frameshift, and nonsense mutations) solid tumor, as determined by local or central testing of tumor or circulating tumor nucleic acid in blood; as detailed below.
- Group 1 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion previously treated with a platinum-based chemotherapy.
- Group 2 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion not previously treated with a platinum-based chemotherapy, including those who have not had any systemic therapy. Prior platinum chemotherapy in the neoadjuvant and adjuvant setting is permitted if the last dose of platinum was 4 months or more before the first dose of study drug.
- Group 3 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit and was previously treated with cabozantinib and/or vandetanib.
- Group 4 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit and was not previously treated with cabozantinib and/or vandetanib.
- Group 5 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion, have previously received standard of care (SOC) appropriate for their tumor type (unless there is no accepted standard therapy for the tumor type or the Investigator has determined that treatment with standard therapy is not appropriate), and must not have been eligible for any of the other groups.
- Group 6 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET fusion or mutation that was previously treated with a selective tyrosine kinase inhibitor (TKI) that inhibits RET
- Group 7 - participants must have a pathologically documented, definitively diagnosed advanced solid tumor with an oncogenic RET mutation previously treated with SOC appropriate for the tumor type and not eligible for any of the other groups
- Group 8 - participants must have pathologically documented, definitively diagnosed locally advanced or metastatic NSCLC with a RET fusion that was previously treated with a platinum based chemotherapy (China only).
- Group 9 - participants must have pathologically documented, definitively diagnosed advanced MTC that had progressed within 14 months prior to the Screening Visit, and was not previously treated with systemic therapy (except prior cytotoxic chemotherapy is allowed) for advanced or metastatic disease (China only).
- Participants must have non-resectable disease.
- Dose expansion (Phase 2): Participants in all groups (except Group 7) must have measurable disease per RECIST v1.1 (or RANO, criteria if appropriate for tumor type).
- Participants agrees to provide tumor tissue (archived, if available or a fresh biopsy) for RET status confirmation and is willing to consider an on-treatment tumor biopsy, if considered safe and medically feasible by the treating Investigator. For Phase 2, Group 6, participants are required to undergo a pretreatment biopsy to define baseline RET status in tumor tissue.
- Participants has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
Key Exclusion Criteria:
- Participant's cancer has a known primary driver alteration other than RET. For example, NSCLC with a targetable mutation in EGFR, ALK, ROS1 or BRAF; colorectal with an oncogenic KRAS, NRAS, or BRAF mutation.
-
Participants had any of the following within 14 days prior to the first dose of study drug:
- Platelet count < 75 × 10^9/L.
- Absolute neutrophil count < 1.0 × 10^9/L.
- Hemoglobin < 9.0 g/dL (red blood cell transfusion and erythropoietin may be used to reach at least 9.0 g/dL, but must have been administered at least 2 weeks prior to the first dose of study drug.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present; > 5 × ULN if hepatic metastases are present.
- Total bilirubin > 1.5 × ULN; > 3 × ULN with direct bilirubin > 1.5 × ULN in presence of Gilbert's disease.
- Estimated (Cockcroft-Gault formula) or measured creatinine clearance < 40 mL/min.
- Total serum phosphorus > 5.5 mg/dL
- QT interval corrected using Fridericia's formula (QTcF) > 470 msec or history of prolonged QT syndrome or Torsades de pointes, or familial history of prolonged QT syndrome.
- Clinically significant, uncontrolled, cardiovascular disease.
- Central nervous system (CNS) metastases or a primary CNS tumor that is associated with progressive neurological symptoms.
- Clinically symptomatic interstitial lung disease or interstitial pneumonitis including radiation pneumonitis
- Participants in Groups 1-5 and 7 (Phase 2) previously treated with a selective RET inhibitor
- Participant had a major surgical procedure within 14 days of the first dose of study drug
- Participant had a history of another primary malignancy that had been diagnosed or required therapy within the a year prior to the study
- Pregnant or breastfeeding female participants
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03037385
Locations
Show 72 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
| Study Director: | Clinical Trials | Hoffmann-La Roche |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT03037385 |
| Other Study ID Numbers: |
BO42863 2016-004390-41 ( EudraCT Number ) BLU-667-1101 ( Registry Identifier: CT.Gov ) |
| First Posted: | January 31, 2017 Key Record Dates |
| Last Update Posted: | April 11, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Hoffmann-La Roche:
|
RET Lung RET Thyroid RET fusion RET alteration RET mutation RET positive RET inhibitor RET altered RET rearrangement RET NSCLC RET medullary thyroid cancer RET-rearranged NSCLC RET-rearranged thyroid M918T TRIM33-RET |
RET fusion lung cancer RET fusion thyroid cancer lung cancer mutation BLU 667 RET tyrosine kinase RET gene mutation RET kinase RET MTC advanced lung cancer advanced non small cell lung cancer metastatic lung cancer KIF5B-RET CCDC6-RET NCOA4-RET advance solid tumor |
Additional relevant MeSH terms:
|
Carcinoma Neoplasms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Adenocarcinoma Colonic Neoplasms Thyroid Neoplasms Neuroendocrine Tumors Colorectal Neoplasms Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Head and Neck Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Thyroid Cancer, Papillary |
Neoplasms by Site Carcinoma, Neuroendocrine Neoplasms by Histologic Type Thoracic Neoplasms Intestinal Neoplasms Neoplasms, Glandular and Epithelial Respiratory Tract Neoplasms Bronchial Neoplasms Carcinoma, Bronchogenic Endocrine Gland Neoplasms Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Adenocarcinoma, Papillary Gastrointestinal Diseases Digestive System Diseases |